Product Information

LUBIPROSTONE 8 MCG CAPSULE is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.5674 per EA under NDC 70710164106. Its NADAC has been published 152 times since Dec 20, 2023.

FDA first approved this application on Mar 23, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LUBIPROSTONE 8 MCG CAPSULE

Lubiprostone
$0.5674per EA

Strength

8 ug/1

NDC

70710164106

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

LUBIPROSTONE

Approval Type

Generic (ANDA)

FDA Application

ANDA214131

FDA Approved

3/23/2023

TE Code

AB

On Market Since

3/23/2023

Pharmacological Classes

Chloride Channel Activator
Chloride Channel Activators

Price Statistics

The NADAC for LUBIPROSTONE 8 MCG CAPSULE has been published 152 times since Dec 20, 2023, and over the history we have for it it has declined 54.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.5674 per EA
All-time high$1.2567 (Jan 10, 2024)
All-time low$0.5447 (Nov 20, 2024)
52-week high$0.7562
52-week low$0.5493
Median price$0.7454
Average price$0.7454
Largest weekly change+39.5% (Jun 19, 2024)
Weeks tracked152
Tracking sinceDec 20, 2023

Price History

1W

0.0%

1M

+0.4%

3M

+2.0%

6M

-25.0%

1Y

-18.8%

3Y

N/A

5Y

N/A

All

-54.9%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of LUBIPROSTONE 8 MCG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 8 MCG CAPSULE, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.5674 per EA (NDC 70710164106), effective Nov 11, 2026.

How has the price of LUBIPROSTONE 8 MCG CAPSULE changed over time?

Over the history we have for it, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has declined 54.9%. It has been tracked across 152 weekly CMS publications since Dec 20, 2023.

What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 8 MCG CAPSULE?

Since Dec 20, 2023, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has ranged from a low of $0.5447 (Nov 20, 2024) to a high of $1.2567 (Jan 10, 2024), with a median of $0.7454 per EA.

Are there cheaper alternatives to LUBIPROSTONE 8 MCG CAPSULE?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 8 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures LUBIPROSTONE 8 MCG CAPSULE?

LUBIPROSTONE 8 MCG CAPSULE (NDC 70710164106) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.